Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Larimar Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$3.47

-0.09 (-2.5%)

B 60Pipeline Score Undervalued Biotech · Commercial
Market Cap
358.40 M
EPS
-2.08
P/E Ratio
-
Value Trade
5.97 M
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • R&D Expenses

    25.03 M

  • Operating CF

    -44.61 M

  • Total Assets

    208.51 M

  • Total Liabilities

    50.48 M

  • Equity

    158.03 M

  • D/E Ratio

    12,345

-10.39 %
Week
-25 %
1 Month
12.75 %
3 Month
3.29 %
6 Month
-74.44 %
5 Year
-98.56 %
All Time
Cash Data
Stable

  • Cash Position

    200.39 M

  • Monthly Burn

    14.87 M

  • Runway

    12.6 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 14, 2026
Overview
Volume
1.56 M
52 Week Range
1.80 - 6.42
% held by Insiders
51.52 %
% held by Institutions
43.87 %
Enterprise Value
161.79 M
Total Shares
103.85 M
Short %
13.04 %
Float Shares
61.69 M
Company Description
HQ: THREE BALA PLAZA EAST. SUITE 5...
Employees:71
https://www.larimartx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
BLA Filing example
nomlabofusp Friedreich's ataxia
BLA
—
Biologics
Rare Diseases
nomlabofusp Friedreich's ataxia
BLA
—
Biologics
Rare Diseases
nomlabofusp Friedreich's ataxia
BLA
—
Biologics
Rare Diseases
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B60
Pipeline Score
$3.3B
Pipeline Value
Undervalued
Valuation Signal
6
Drugs Scored
15.0x
rNPV / MCap
Top 87%
Micro Cap
(rank 119 of 905)
Percentile Rank
Larimar Therapeutics, Inc. holds a solid B-grade pipeline (60/100), with $10.9B risk-adjusted pipeline value, led by ZGN-1061 in Type 2 Diabetes Mellitus (Phase 2), across $126B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
ZGN-1061
Small molecule		Type 2 Diabetes MellitusPhase 2NCT0325436823% $4.7B COMPLETED 188 - -Feb 22, 2019 -May 24, 2019
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
nomlabofusp
Friedreich's Ataxia
Phase 3
2025-06-23
nomlabofusp
Friedreich's Ataxia
Phase 3
2025-06-23
nomlabofusp
Friedreich's Ataxia
Phase 3
2025-06-23
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in LRMR
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
LRMR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LRMR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LRMR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
LRMR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
LRMR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Larimar Therapeutics, Inc. (LRMR) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How LRMR ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Rare Neurological Disorders #30 of 46 PHASE 2 CTI-1601
IONS BIIB SRPT
$139.4B 0.97 FOLLOWER